---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-23-001534"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2023-11-24T23:59:59+00:00"
generated_at: "2026-06-07T21:47:48.416468+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical terminates named executive officer Scott Dunbar in subsidiary workforce reduction

## Summary
- Scott Dunbar terminated without cause effective Nov 20, 2023 as part of Cortigent workforce reduction.
- Dunbar was a named executive officer in 2023 proxy and former Acting CEO of predecessor Second Sight Medical.
- Severance includes ~$70,000 cash payment and COBRA premium reimbursement for up to six months.
- Company intends to enter a separation and release agreement with Dunbar.

## SEC filing metadata
- accession: 0001753926-23-001534
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2023-11-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392623001534/0001753926-23-001534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392623001534/g083867_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-23-001534
- JSON: https://secwatch.observer/filing/0001753926-23-001534.json
- Plain text: https://secwatch.observer/filing/0001753926-23-001534.txt

## Key facts
- Executive change
  Scott Dunbar departed as Named Executive Officer at Vivani Medical, Inc..
  - Action: terminated without cause
  - Role: Named Executive Officer
  source text: the Company terminated without cause the employment of Scott Dunbar, a named executive officer in the Company’s 2023 proxy statement and former Acting Chief Executive Officer of the Company’s predecessor, Second Sight Medical Products, Inc., effective as of November 20, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1266806/000175392623001534/0001753926-23-001534-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.